Clinical-stage biotech Dimerix has achieved a key milestone with the first paediatric site opening for its ACTION3 Phase 3 clinical ...
Vous n'êtes pas connecté
- English
- Français
- عربي
- Español
- Deutsch
- Português
- русский язык
- Català
- Italiano
- Nederlands, Vlaams
- Norsk
- فارسی
- বাংলা
- اردو
- Azərbaycan dili
- Bahasa Indonesia
- Հայերեն
- Ελληνικά
- Bosanski jezik
- українська мова
- Íslenska
- Türkmen, Түркмен
- Türkçe
- Shqip
- Eesti keel
- magyar
- Қазақ тілі
- Kalaallisut ; kalaallit oqaasii
- Lietuvių kalba
- Latviešu valoda
- македонски јазик
- Монгол
- Bahasa Melayu ; بهاس ملايو
- ဗမာစာ
- Slovenščina
- тоҷикӣ ; toğikī ; تاجیکی
- ไทย
- O'zbek ; Ўзбек ; أۇزبېك
- Tiếng Việt
- ភាសាខ្មែរ
- རྫོང་ཁ
- Soomaaliga ; af Soomaali
Maroc - STOCKHEAD.COM.AU - A La Une - 12/Sep 03:41
Key paediatric milestone reached in Dimerix’s kidney-disease drug trial
Clinical-stage biotech Dimerix has achieved a key milestone with the first paediatric site opening for its ACTION3 Phase 3 clinical ...
Articles similaires
Dimerix first patient completes Phase 3 trial and enters into long-term DMX-200 Open Label Extension study
stockhead.com.au - 10/Sep 23:38
Dimerix has enrolled the first patient into the Open Label Extension study for its kidney disease drug candidate DMX-200 after ...
First Patients Treated in Phase 2 Clinical Trial of STAT3 Inhibitor in Combination with Radiation for the Treatment of Glioblastoma
drugs.com - 09/Sep 20:09
HOUSTON, Sept. 9, 2024. Moleculin Biotech, Inc., ("Moleculin" or the "Company), a Phase 3 clinical-stage pharmaceutical company with a broad portfolio...
Bio Curious: How Dimerix negotiates the ‘valleys of death’ on the winding road to drug approval
stockhead.com.au - 04/Sep 20:45
Despite many obstacles, Dimerix is getting to the pointy end of things with its kidney drug trial program. ...
Bio Curious: How Dimerix negotiates the ‘valleys of death’ on the winding road to drug approval
stockhead.com.au - 04/Sep 20:45
Despite many obstacles, Dimerix is getting to the pointy end of things with its kidney drug trial program. ...
Unicycive Therapeutics Announces Submission of the New Drug Application (NDA) to the U.S. FDA for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis
drugs.com - 03/Sep 01:09
LOS ALTOS, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing...
Bharat Biotech, Alopexx Inc of US to co-develop, commercialise anti-microbial vax AV0328
times of india - 11/Sep 09:13
Bharat Biotech has teamed up with Alopexx Inc to co-develop and market the broad-spectrum antimicrobial vaccine AV0328 in India and other low-income...
Bharat Biotech, Alopexx Inc of US to co-develop, commercialise anti-microbial vax AV0328
times of india - 11/Sep 09:13
Bharat Biotech has teamed up with Alopexx Inc to co-develop and market the broad-spectrum antimicrobial vaccine AV0328 in India and other low-income...
Sydney Metro hits key milestone
infrastructuremagazine.com.au - 12/Sep 23:34
Sydney Metro - Western Sydney Airport lineConstruction on the new Sydney Metro line has reached new heights with the completion of one of its most...
Sydney Metro hits key milestone
infrastructuremagazine.com.au - 12/Sep 23:34
Sydney Metro - Western Sydney Airport lineConstruction on the new Sydney Metro line has reached new heights with the completion of one of its most...
Les derniers communiqués
-
Aucun élément